4-硝基-N-(2-甲苯基)苯磺酰胺 | 109847-18-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-硝基-N-(2-甲苯基)苯磺酰胺
• 英文名称: 4-nitro-N-(2-tolyl)benzenesulfonamide
• 英文别名: 4-nitro-N-(o-tolyl)benzenesulfonamide；4-nitro-N-o-tolyl-benzenesulfonamide；N-nosyl-o-toluidine；4-nitro-benzenesulfonic acid o-toluidide；4-Nitro-benzolsulfonsaeure-o-toluidid；4-nitro-N-2-tolylbenzenesulfonamide；N-(2-methylphenyl)-4-nitrobenzenesulfonamide
• CAS: 109847-18-9
• 化学式: C₁₃H₁₂N₂O₄S
• mdl: MFCD00705162
• 分子量: 292.315
• InChiKey: MKUXLTTXEGASSZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  100
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-硝基-N-(2-甲苯基)苯磺酰胺 在 sodium tetrahydroborate 、 nickel(II) chloride hexahydrate 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以100%的产率得到4-氨基-n-(2-甲基苯基)苯磺酰胺
  参考文献：
  名称：

  Synthesis and biological evaluation of naphthoquinone analogs as a novel class of proteasome inhibitors

  摘要：

  Screening of the NCI Diversity Set-1 identified PI-083 (NSC-45382) a proteasome inhibitor selective for cancer over normal cells. Focused libraries of novel compounds based on PI-083 chloronaphthoquinone and sulfonamide moieties were synthesized to gain a better understanding of the structure-activity relationship responsible for chymotrypsin-like proteasome inhibitory activity. This led to the demonstration that the chloronaphthoquinone and the sulfonamide moieties are critical for inhibitory activity. The pyridyl group in PI-083 can be replaced with other heterocyclic groups without significant loss of activity. Molecular modeling studies were also performed to explore the detailed interactions of PI-083 and its derivatives with the beta 5 and beta 6 subunits of the 20S proteasome. The refined model showed an H-bond interaction between the Asp-114 and the sulfonamide moiety of the PI-083 in the beta 6 subunit. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2010.06.038
• 作为产物：
  描述：

  邻甲苯胺 、 对硝基苯磺酰氯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 以94%的产率得到4-硝基-N-(2-甲苯基)苯磺酰胺
  参考文献：
  名称：

  伯芳香胺的高特异性N-单甲基化

  摘要：

  提出了一种在非常温和的条件下将芳族伯胺具体转化为N-单甲基衍生物的合成方法。用4-硝基苯磺酰（壬基）氯化物处理苯胺，以高产率产生相应的磺酰胺2。磺酰胺2与重氮甲烷溶液的随后N-甲基化反应是快速且定量的。使用试剂体系巯基乙酸/ 1,8-二氮杂双环[5.4.0]十一碳-7-烯（DBU）可以轻松进行烷基保护基的除去，得到N-单甲基化的芳族胺4。该程序方便，高效，并产生了N-一甲基苯胺。

  DOI：

  10.1016/j.tet.2006.03.104

文献信息

• Assembly of Tetrahydroquinolines and 2-Benzazepines by Pd-Catalyzed Cycloadditions Involving the Activation of C(sp³)–H Bonds
  作者：Xandro Vidal、José Luis Mascareñas、Moisés Gulías

  DOI：10.1021/acs.orglett.1c01594

  日期：2021.7.16

  Cycloaddition reactions are among the most practical strategies to assemble cyclic products; however, they usually require the presence of reactive functional groups in the reactants. Here, we report a palladium-catalyzed formal (4 + 2) cycloaddition that involves the activation of C(sp3)–H bonds and provides a direct, unconventional entry to tetrahydroquinoline skeletons. The reaction utilizes amidotolyl

  环加成反应是组装环状产物最实用的策略之一。然而，它们通常需要反应物中存在反应性官能团。在这里，我们报告了钯催化的正式 (4 + 2) 环加成反应，该反应涉及 C(sp 3 )–H 键的活化，并提供了一种直接的、非常规的进入四氢喹啉骨架的方法。该反应利用酰胺基前体和丙二烯作为环化伙伴，并由 Pd(II) 前体与特定的N-乙酰化氨基酸配体组合催化。反应性可以扩展到邻甲基苄基酰胺，它为在正式的 (5 + 2) 环化过程中组装有吸引力的四氢-2-苯并氮杂提供了条件。
• Highly<i>ortho</i>-Selective Chlorination of Anilines Using a Secondary Ammonium Salt Organocatalyst
  作者：Xiaodong Xiong、Ying-Yeung Yeung

  DOI：10.1002/anie.201607388

  日期：2016.12.23

  An organocatalytic, highly facile, efficient, and regioselective ortho‐chlorination of anilines is described. A secondary ammonium chloride salt has been employed as the catalyst and the reaction can be conducted at room temperature without protection from air and moisture. In addition, the reaction is readily scalable and the catalyst can be recycled and reused. This catalytic protocol has been applied

  描述了苯胺的有机催化，高度简便，有效和区域选择性邻氯化反应。已经使用仲氯化铵盐作为催化剂，并且该反应可以在室温下进行而无需保护空气和湿气。另外，该反应易于扩展，并且催化剂可以再循环和再利用。该催化方案已用于高效合成高效c-Met激酶抑制剂。机理研究表明，仲氯化铵盐的独特结构特征对于亲电子邻氯化反应的催化和区域选择性均很重要。
• Metal Free Bi(hetero)aryl Synthesis: A Benzyne Truce-Smiles Rearrangement
  作者：Catherine M. Holden、Shariar M. A. Sohel、Michael F. Greaney

  DOI：10.1002/anie.201510236

  日期：2016.2.12

  A new benzyne transformation is described that affords versatile biaryl structures without recourse to transition-metal catalysis or stoichiometric amounts of organometallic building blocks. Aryl sulfonamides add to benzyne upon fluoride activation, and then undergo an aryl Truce-Smiles rearrangement to afford biaryls with sulfur dioxide extrusion. The reaction proceeds under simple reaction conditions

  描述了新的苯并炔转化，其提供通用的联芳基结构，而无需求助于过渡金属催化或化学计量的有机金属结构单元。芳基磺酰胺在氟化物活化后加至苯并，然后进行芳基Truce-Smiles重排，得到具有二氧化硫挤出的联芳基。该反应在简单的反应条件下进行，并且具有空间位阻阻转异构二芳基胺的合成的优异范围。
• BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS
  申请人：Genentech, Inc.

  公开号：US20140163024A1

  公开（公告）日：2014-06-12

  Compounds of the formula Ia or Ib: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, A, X 1 , X 2 , X 3 , X 4 , Y, Z, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , and R 8 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.

  公式Ia或Ib的化合物：或其药用可接受的盐，其中m、n、p、q、r、A、X1、X2、X3、X4、Y、Z、R1、R2、R3、R4、R5、R6、R7和R8如本文所定义。还公开了制备这些化合物的方法以及将这些化合物用于治疗炎症性疾病如关节炎的方法。
• PROTEASOME INHIBITORS FOR SELECTIVELY INDUCING APOPTOSIS IN CANCER CELLS
  申请人：Lawrence Harshani

  公开号：US20110201609A1

  公开（公告）日：2011-08-18

  The subject invention concerns compounds having activity as inhibitors of proteasomes and methods of using the subject compounds. In one embodiment, a compound of the invention has the chemical structure shown in formula I: wherein R 1 is an organic cyclic ring structure bonded to a sulfonamide structure; R 2 is H, halogen, alkyl, —NR 6 R 7 , or heteroalkyl; R 3 is H, halogen, —OH, —O-alkyl, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, —NO 2 , —NH 2 or substituted amines; R 4 is H, alkyl, heteroalkyl, aryl, or heteroaryl, any of which can be optionally substituted with one or more of —NO 2 , alkyl, heteroalkyl, aryl, or heteroaryl, or halogen; R 5 is H, —OH, halogen, alkyl, aryl, heteroaryl, cycloalkyl, heterocycloalkyl, —O-alkyl, —O-aryl, heteroalkyl, —NO 2 , —NH 2 , or substituted amine; and R 6 and R 7 are independently H, O, alkyl, aryl, heterocycloalkyl, or heteroaryl, or together can form a heterocycloalkyl or a heteroaryl, any of which can be optionally substituted with one or more of —NO 2 , alkyl, heteroalkyl, aryl, or halogen; or a pharmaceutically acceptable salt or hydrate thereof. In another embodiment, a compound of the invention has the chemical structure shown in formula II: wherein Q, W, X, Y, Z are each independently carbon, oxygen, or nitrogen; R 1 is H, or X 1 R 8 ; R 2 is heteroalkyl, which can be optionally substituted with one or more of —OH, halogen, —C(O)OR 4 , alkyl, heteroalkyl, heterocycloalkyl, or heteroaryl; R 3 is heterocycloalkyl, aryl, heteroaryl, any of which can be optionally substituted with one or more of a halogen or —OH; and R 4 is H or alkyl; R 5 is halogen, alkyl or nitro; R 6 is nitro, X 2 R 9 or a halogen; R 7 is H or alkyl; R 8 is H, alkyl, aryl, CH 2 -alkyl-aryl, -alkyl-C(O)OH, or alkyl-tetrazole (aromatic and aliphatic heterocyclic groups); R 9 is H or alkyl; X 1 is oxygen, nitrogen, or sulfur; X 2 is oxygen, nitrogen, or sulfur; or a pharmaceutically acceptable salt or hydrate thereof.

  本发明涉及作为蛋白酶体抑制剂的化合物及使用该化合物的方法。在一种实施方式中，本发明的化合物具有公式I所示的化学结构：其中，R1是与磺酰胺结构键合的有机环状环结构；R2是H、卤素、烷基、-NR6R7或杂环烷基；R3是H、卤素、-OH、-O-烷基、烷基、环烷基、杂环烷基、芳基、杂芳基、-NO2、-NH2或取代胺；R4是H、烷基、杂烷基、芳基或杂芳基，其中任何一个都可以选择性地取代一个或多个-NO2、烷基、杂烷基、芳基或杂芳基或卤素；R5是H、-OH、卤素、烷基、芳基、杂芳基、环烷基、杂环烷基、-O-烷基、-O-芳基、杂烷基、-NO2、-NH2或取代胺；R6和R7分别是H、O、烷基、芳基、杂环烷基或杂芳基，或者一起形成杂环烷基或杂芳基，其中任何一个都可以选择性地取代一个或多个-NO2、烷基、杂烷基、芳基或卤素；或其药学上可接受的盐或水合物。在另一种实施方式中，本发明的化合物具有公式II所示的化学结构：其中，Q、W、X、Y、Z分别独立地是碳、氧或氮；R1是H或X1R8；R2是杂环烷基，可以选择性地取代一个或多个-OH、卤素、-C（O）OR4、烷基、杂烷基、杂环烷基或杂芳基；R3是杂环烷基、芳基、杂芳基，其中任何一个都可以选择性地取代一个或多个卤素或-OH；R4是H或烷基；R5是卤素、烷基或硝基；R6是硝基、X2R9或卤素；R7是H或烷基；R8是H、烷基、芳基、CH2-烷基-芳基、-烷基-C（O）OH或烷基-四唑（芳香和脂肪族杂环基）；R9是H或烷基；X1是氧、氮或硫；X2是氧、氮或硫；或其药学上可接受的盐或水合物。